Iovance Biotherapeutics (IOVA) Income towards Parent Company (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Income towards Parent Company for 17 consecutive years, with -$79.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 31.98% year-over-year to -$79.0 million; the TTM figure through Mar 2026 stood at -$273.4 million (up 27.16% YoY), while the FY2025 annual figure was -$310.5 million, up 16.58% from the prior year.
• Income towards Parent Company eased to -$79.0 million in Q1 2026 per IOVA's latest filing, from $8.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $8.5 million in Q4 2025 and bottomed at -$119.2 million in Q1 2022.
• Historically, Income towards Parent Company has averaged -$95.8 million across 5 years, with a median of -$105.3 million in 2022.
• Annual changes were most pronounced in 2022 — Income towards Parent Company sank 52.98% — and 2025, when it surged 110.84%.
• Iovance Biotherapeutics' Income towards Parent Company stood at -$105.3 million in 2022, then decreased by 10.46% to -$116.3 million in 2023, then surged by 32.44% to -$78.6 million in 2024, then soared by 110.84% to $8.5 million in 2025, then slumped by 1027.24% to -$79.0 million in 2026.
• Business Quant data shows IOVA's Income towards Parent Company at -$79.0 million in Q1 2026, $8.5 million in Q4 2025, and -$91.3 million in Q3 2025.